Welcome to Iaso Therapeutics

Vaccines have protected humankind from many deadly infections including smallpox, yellow fever, and tetanus, saving millions of lives. However, the rampage of the COVID-19 over the world serves as a painful reminder of the lack of effective vaccines against many other diseases. Novel technologies that can be readily deployed for new vaccines, especially against newly emerged pathogens, are urgently needed.

Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases.

Mutant Qβ Platform

Iaso’s initial product offering is a disruptive new virus-like particle, mutant Qβ, that shows superiority in generating antibodies of interest when compared to conjugate carrier proteins like Keyhole Limpet Hemocyanin, diphtheria toxoid, tetanus toxoid, and cross reactive material-197 (CRM-197).

mQβ is now sold by Fina Biosolutions

Recent Company News

  • Vaccine-tech startup hopes it can make lightning strike again

    Crain’s Detroit covers Iaso Therapeutics. The interview reports on the history and funding of Iaso. View the article from Crain's Detroit Business

  • A new tool to fight cancer, infections, addiction

    A soccer ball-shaped, nanoparticle-sized vaccine delivery platform called Q-Beta might hold the key to unlocking treatments for any number of viruses and diseases — from cancers to infections and even opioid addiction — thanks to the work of a research team that got its start at Michigan State University.